News | Implantable Cardiac Monitor (ICM) | September 07, 2021

Implantable Cardiac Monitors Predict Complications in Selected Post-myocardial Infarction Patients

Sensitivity in detection of arrhythmias was three times higher in the ICM group in this ESC Hot Line session

The Medtronic Reveal Linq implantable cardiac monitor (ICM) was used in the SMART-MI study. It is inserted under the skin in a simple, fast outpatient procedure. The device is smaller than a AAA battery.

The Medtronic Reveal Linq implantable cardiac monitor (ICM) was used in the SMART-MI study. It is inserted under the skin in a simple, fast outpatient procedure. The device is smaller than a AAA battery.


September 7, 2021 — Remote monitoring of implantable cardiac monitors (ICMs) is highly effective for early detection of serious arrhythmias in high-risk post-infarction patients with cardiac autonomic dysfunction and moderately reduced ejection fraction. That was the finding from the SMART-MI late breaking research presented in a Hot Line session at the 2021 European Society of Cardiology (ESC) Congress.[1]

Patients with severely reduced left ventricular ejection fraction (LVEF) of 35% or below after myocardial infarction (MI) are candidates for prophylactic implantation of a cardioverter defibrillator. However, the vast majority of fatal and non-fatal complications after MI occur in patients with LVEF above 35%, for whom no specific preventive measures exist.

Previous studies in post-MI patients with reduced LVEF suggested that cardiovascular complications are preceded by arrhythmic events. However, as most of these arrhythmias are asymptomatic or subclinical, their detection escapes conventional follow-up. This study examined whether ICMs could provide early detection of such arrhythmias.[2]

SMART-MI was a prospective, randomized, open-label trial conducted between May 2016 and February 2021 at 33 centers in Germany and Austria. The study enrolled MI survivors with LVEF 36–50% and cardiac autonomic dysfunction, which is associated with poor outcomes after MI (including arrhythmias and sudden death) independently of ejection fraction. Autonomic dysfunction was identified by a core lab using digital biomarkers calculated from a 20-minute high-resolution resting electrocardiogram (ECG).[3,4,5]

A total of 400 patients were randomly allocated in a 1:1 ratio to ICM implantation and remote monitoring or conventional follow-up. The monitor was implanted subcutaneously using a minimally invasive procedure and a telemonitoring system transmitted a daily report to an ICM core lab. Local study centers were informed about detection of serious arrhythmic events by the ICM core lab.

The primary endpoint was time to detection of serious arrhythmic events, which included atrial fibrillation lasting 6 minutes or longer, higher-degree atrioventricular block, fast non-sustained ventricular tachycardia (VT), and sustained VT/ventricular fibrillation.  

“All arrhythmias included in the primary composite endpoint have been associated with poor outcomes or would trigger appropriate therapies in patients with an implantable cardioverter defibrillator (ICD),” explained principal investigator Professor Axel Bauer of the Medical University of Innsbruck, Austria.

During a median follow-up of 21 months, the primary endpoint occurred in 60 (29.9%) patients in the ICM group and 12 (6.0%) patients in the control group (hazard ratio [HR] 6.3; 95% confidence interval [CI] 3.4–11.8; p<0.0001). The cumulative 3-year detection rate of serious arrhythmic events was 41.2% in the ICM group compared to 10.7% in the control group.

Secondary endpoints included major adverse cardiac and cerebrovascular events (MACCE; cardiovascular mortality, stroke, systemic arterial thromboembolism and unplanned hospitalization for decompensated heart failure). Detection of serious arrhythmic events strongly predicted subsequent MACCE in both the ICM group (HR 6.8; 95% CI 2.9–16.2; p<0.001) and the control group (HR 7.3; 95% CI 2.4–22.8; p<0.001).

Professor Bauer noted that the prognostic impact of serious arrhythmic events was not related to the mode of detection, as the positive predictive accuracies were 61% and 62% in the ICM and control groups, respectively (p=0.990). 

“The important difference was the sensitivity in detection, which was three times higher in the ICM group (61% vs. 20%; p=0.007). This means that adverse outcomes were three times more likely to be detected early in the ICM group,” Bauer said.

An increased number of diagnostic and therapeutic measures were observed in the ICM group, including implantation of ICDs or pacemakers, electrophysiological studies, catheter ablations, and initiation of oral anticoagulation. These measures were administered by treating physicians at their own discretion but in accordance with applicable guidelines.
 
“Because this was designed as a diagnostic study, it cannot provide information about the effect of preventive measures on clinical outcomes. Optimal treatment pathways have yet to be established,” Bauer said.

“The study found that post-infarction patients with cardiac autonomic dysfunction and only moderately reduced LVEF developed a high number of serious subclinical arrhythmic events that could be detected early and effectively with ICMs," Bauer concluded. "The spectrum and frequency of arrhythmias in these patients was comparable to that of post-infarction patients with reduced LVEF, who are currently candidates for prophylactic ICD therapy. Our study supports the use of ICMs in high-risk post-MI patients with moderately reduced LVEF and cardiac autonomic dysfunction as a sensitive tool for continuous risk assessment.”

Funding for the study was funded by the German Centre for Cardiovascular Research (Deutsches Zentrum für Herzkreislaufforschung – DZHK). The Medtronic Bakken Research Center provided the ICM devices and telemonitoring system as well as personnel costs for the ICM core lab.

Bauer received speaker honoraria from Medtronic that was related to the study.

Find more ESC Hot Line late-breaking study news

References:

1. Implantable cardiac monitors in high-risk post-infarction patients with cardiac autonomic dysfunction and moderately reduced left ventricular ejection fraction - A randomized trial. https://clinicaltrials.gov/ct2/show/NCT02594488.

2. Hamm W, Rizas KD, von Stülpnagel L, et al. Implantable cardiac monitors in high-risk post-infarction patients with cardiac autonomic dysfunction and moderately reduced left ventricular ejection fraction: Design and rationale of the SMART-MI trial. Am Heart J. 2017;190:34–39.

3. Rizas KD, Nieminen T, Barthel P, et al. Sympathetic activity–associated periodic repolarization dynamics predict mortality following myocardial infarction. J Clin Invest. 2014;124:1770–1780.

4. Bauer A, Klemm M, Rizas KD, et al. Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study. Lancet. 2019;394:1344–1351.

5. Bauer A, Kantelhardt JW, Barthel P, et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet. 2006;367:1674–1681.
 


Related Content

News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 28, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been ...

Home November 28, 2023
Home
News | Cardiovascular Clinical Studies

November 27, 2023 — Esperion announced the presentation of results from a pre-specified, exploratory analysis of CLEAR ...

Home November 27, 2023
Home
News | Cardiovascular Clinical Studies

November 22, 2023 — The first clinical trial to challenge the routine implantation of a defibrillator in myocardial ...

Home November 22, 2023
Home
News | Cardiovascular Clinical Studies

November 15, 2023 — Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our ...

Home November 15, 2023
Home
News | Cardiovascular Clinical Studies

November 6, 2023 — Bristol Myers Squibb announced that research across the company’s cardiovascular franchise will be ...

Home November 06, 2023
Home
News | Cardiovascular Clinical Studies

October 20, 2023 — JenaValve Technology, Inc., developer and manufacturer of the Trilogy Transcatheter Heart Valve (THV) ...

Home October 20, 2023
Home
News | Cardiovascular Clinical Studies

October 12, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home October 12, 2023
Home
Subscribe Now